Hengrui Pharma(SH:600276) Ge Long Hui·2025-09-18 08:12Core Viewpoint - The Hong Kong stock market indices experienced a collective decline, while leading pharmaceutical company Heng Rui Medicine (1276.HK) saw a significant increase, reaching a new high since its IPO, driven by positive regulatory news regarding its drug application [1] Company Performance - Heng Rui Medicine's stock price rose by 7.18% to HKD 91, achieving a market capitalization exceeding HKD 600 billion [1] - Since its IPO on May 23, the stock has appreciated by 106.58% from the initial price of HKD 44.05 [1] Regulatory News - The company's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., received a "Notice of Acceptance" from the National Medical Products Administration for its application for a new indication of the drug SHR-A1811 [1] - The drug is intended for adult patients with locally advanced or metastatic HER2-positive breast cancer who have previously received one or more anti-HER2 therapies and is now included in the priority review process [1] - SHR-A1811 has already been approved for use in treating adult patients with non-small cell lung cancer (NSCLC) that have HER2 activation mutations and have previously undergone at least one systemic treatment [1]